BIO International Convention San Diego 2024

BIO International Convention, the premier partnering event in the biotechnology sector, will be held from 3-6 June 2024 at the San Diego Convention Center, California. The conference aims to establish collaborations, strategic alliances and business opportunities between startups, companies, institutions, government agencies and investors. 

It represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organisations in the United States and more than 30 countries. 

Dedicated to the research and development of biotechnology products for healthcare, agriculture, industry and the environment, these members range from small entrepreneurs developing their first product to large companies with international reach. 

If you would like to explore San Diego's biotech ecosystem and showcase your company, join the ICEX call. Registration is open until 3 June 2024.

Why should you attend the BIO International Convention? 

• Make strategic alliances 
• Find funding for your project or solution 
• Attract new clients 
• Promote your offering to key industry players 
• Find information of high scientific and financial value

Monday, June 3, from 6 pm to 7:30 pm at Hotel Hilton Bayfront San Diego -The Pool Club, 1 Park Boulevard, CA 92101

The Government of Catalonia, ACCIÓ-Catalonia Trade and Investment, and Biocat will host the Catalonia BioNetworking Event, a networking event for all interested in exploring the US and the Catalan Biotech ecosystems. For companies and organizations willing to create synergies, share knowledge, and better understand the biotechnology ecosystems of North America and Catalonia. 

Register if you would like to explore San Diego's biotech ecosystem and showcase your company. Registration is open until June 3, 2024.

Building Capacities in the Industry for Secondary Uses of Health Data: The EHDS Framework

Monday, June 03, 2024
1:45 PM - 2:45 PM
Breakout Session 24BC

On May 3, 2022, the European Commission published its draft regulation on the European Health Data Space (EHDS). This proposal aims to achieve two main objectives. The first is to improve the provision of cross-border healthcare in the EU, regardless of the patient’s location in Member States. The second is to enable the secondary use of electronic health data by researchers, companies, innovators, and public institutions (data users). This session, chaired by the Council of European BioRegions, representing over 40 health innovation ecosystems in Europe, brings together experts from industry, the European Commission, clinical institutions, and health data experts to discuss the talent needs and skills gaps to fulfill industry's expectations.

Moderator

• Montse Daban, PhD, MS, MA, Director of Strategic Foresight and International Relations and President
  - Biocat and The Council of European BioRegions

Speakers

• Jean Marc Bourez, CEO - EIT Health
• Elina Drakvik, Senior lead, Health Data 2030 - Sitra
• Mariano Vázquez, ACA, CEO - ELEM Biotech
• Aenor Sawyer, MD, Director UC Space Health - University of San Francisco
• Brad Ship, Partner - Alira Health

Company Presentation - ELEM Biotech

Monday, June 03, 2024

5:15-5:30

Theater 3

ELEM is a pioneer in biomedical simulation technology, creating virtual human populations for drug & device safety assessment. Its expertise lies in biomedical engineering, biophysical modelling & supercomputing replicating organ function, with an initial focus on cardiovascular disease. Medical trial failures plague drug development, with cardiac safety issues a major concern. ELEM's platform enables supercomputer-based trials to assess drug safety, supporting drug repurposing and accelerating regulatory approval. Its virtual humans provide evidence for decision-making, pipeline optimisation, risk reduction and cost avoidance for pharmaceutical companies, CROs and device manufacturers.

Speakers

• Christopher Morton, CEO - ELEM Biotech

Start-Up Stadium - Oniria Therapeutics

Tuesday, June 04, 2024 

2:00 PM - 4:00 PM 

5B

Oniria Therapeutics, a Barcelona-based SME in precision oncology, aims to revolutionize cancer treatment by bringing to market the first-in-class drug ONR-001, designed for solid and liquid aggressive tumors unresponsive to current treatments, paving the way for novel therapeutic combinations or standalone treatments. From a broader perspective, the advantages of our proposed therapy lie in its precision, which increases the likelihood of achieving high efficacy rates while minimizing adverse effects. Moreover, due to its specific target, it also helps prevent cancer relapse and metastasis, thereby extending patients' life expectancy and improving the effectiveness of the Standard of Care (SoC) by reducing its required dosage. In parallel, Oniria Therapeutics is developing a highly sensitive biosensor (EpiGold-G) to detect epigenetic modifications of DNA from ultra-low amounts of biological material present in a liquid biopsy, which will work of a Companion Diagnostics test test to mitigate clinical trial risks, by selecting the patients that will benefit from the drug and validating therapeutic effects at the molecular level for each patient.

Speakers

• Héctor Garcia Palmer, PhD - Chief Scientific Officier Onira Therapeutics